Incorporating New Guidelines to Lower LDL-C and Reduce ASCVD Risk
- CME / AMA PRA Category 1 Credit™
In late 2018, two new blood cholesterol guidelines were published. To increase the use of risk-assessment tools to identify patients at increased risk for ASCVD, the ACC released a guide to decision-making for primary prevention of ASCVD. The second, jointly published by a large number of societies including the AHA and ACC, updated the recommendations for managing blood cholesterol. This document provided strategies for primary prevention and secondary prevention of ASCVD and approaches for modifying therapy for patients not achieving LDL-C goals.
To achieve the AHA’s 2020 impact goals of improving the cardiovascular health of all Americans by 20%, while reducing deaths attributable to cardiovascular disease and stroke by 20%, clinicians need to incorporate these new guidelines into clinical practice. This activity will provide a review of these recent evidence-based recommendations, as well as information about non-statin agents recommended for use when patients are not at LDL-C goal.
Welcome and Introductions
Evaluating the Need for Primary Prevention
Managing LDL-C to Lower ASCVD Risk: Primary and Secondary Prevention
Q&A Session and Activity Roundup
This activity is intended for cardiologists, internal medicine specialists, and other healthcare providers who manage patients who have hypercholesterolemia and are at a high risk for atherosclerotic cardiovascular disease (ASCVD).
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.
At the conclusion of this activity, participants should be able to:
- Evaluate the need for blood cholesterol management in the primary prevention of ASCVD by using tools recommended in the 2018 AHA/ACC guidelines
- Develop individualized primary prevention strategies for patients with and without severe hypercholesterolemia using the 2018 cholesterol guidelines
- Implement management plans for the secondary prevention of ASCVD using recommendations from the 2018 blood cholesterol guidelines
- Use adjunctive non-statin therapy when secondary prevention with statins alone does not achieve 2018 blood cholesterol guideline goals
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Professor of Medicine
Gerald S. Berenson Endowed Chair in Preventive Cardiology
Tulane University School of Medicine
Tulane Heart and Vascular Institute
New Orleans, LA
Dr. Ferdinand is past Chair of the National Forum for Heart Disease and Stroke Prevention and prior Chief Science Officer and Chair of the Association of Black Cardiologists (ABC). He lectures nationally and internationally and conducted numerous trials in cardiovascular disease, lipids, and cardiometabolic risk, especially in racial/ethnic minorities. Dr Ferdinand’s research has been published in peer-reviewed journals including the New England Journal of Medicine, Journal of the American College of Cardiology, Journal of Clinical Hypertension, American Journal of Cardiovascular Drugs, Clinical Lipidology, Cardiorenal Medicine, and Hypertension.
In 2004, Dr. Ferdinand received the Louis B. Russell, Jr. Memorial Award of the American Heart Association. In 2010, he received an award from the Congressional Black Caucus Health Trust for Journalism, as well as the Charles Drew Award for Medical Excellence from the National Minority Quality Foundation. In 2015, Dr. Ferdinand was inducted into the Association of University Cardiologists. He was awarded the Wenger Award for Medical Leadership in 2017 by WomenHeart and also the 2017 ABC Spirit of the Heart Distinguished Leadership Award. Most recently, he was the 2019 Xavier University recipient of the Champion Award for health equity.
Associate Professor of Medicine (Cardiology)
Emory University School of Medicine
She attended undergraduate school at Georgia Institute of Technology with a degree in applied biology. She earned her medical degree from Medical College of Georgia, and completed both her internal medicine residency and a four-year cardiovascular fellowship at Emory University. Dr. Mehta completed an additional year of specialized fellowship training in women’s heart disease at Cedars-Sinai’s Barbara Streisand Women’s Heart Center.
Dr. Mehta’s clinical interest is heart disease prevention, and behavioral approaches such as exercise, nutrition, and stress reduction for heart disease. Her research is NIH-funded and focuses on chest pain and microvascular dysfunction, and the role of mental stress in heart disease in women. She has presented her work at national cardiology meetings and has published more than 80 manuscripts in journals such as the Journal of American College of Cardiology, European Heart Journal, Circulation, and American Journal of Physiology. In addition to clinical care and research, she teaches medical students, residents, and fellows in the Emory School of Medicine.
Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH: Consultant: Amgen, Sanofi
Puja K. Mehta, MD, FACC, FAHA: Nothing to disclose
Robert Eberhardt, MD, BUSM Course Director: Nothing to disclose
NON-FACULTY CONTENT CONTRIBUTORS
Terry Ann Glauser, MD, MPH; Blair St. Amand; Michael Burk; Elizabeth Drury; Natalie Sanfratello, MPH: Nothing to disclose
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
Jointly provided by Boston University School of Medicine and Rockpointe
This activity is supported by educational funding provided by Amgen.
FIGHTING THE UPHILL BATTLE: Current Evidence in Obesity Management
Credits 1.00 (60 min)
Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS) and the New FDA Blueprint
Credits 3.00 (3 hrs)